Critique: Makary keeps working amid questions over his FDA future

Source: politico
Authors: David Lim, Sophia Cai
URL: https://www.politico.com/news/2026/05/11/makary-keeps-working-amid-questions-over-his-fda-future-00914881

What the article reports

FDA Commissioner Marty Makary continues to perform his official duties — including a scheduled Senate budget testimony and a Financial Times keynote — despite reports that the White House has approved a plan to remove him. President Trump told reporters Friday he was unaware of any firing plan. The piece cites mounting administration frustration with Makary over policy disputes and names former FDA Commissioner Scott Gottlieb as a critical voice.

Factual accuracy — Adequate

Most verifiable claims are grounded in attributable sources. The Senate testimony is confirmed on the record by a named GOP spokesperson ("Yes, it's still on as scheduled"). The Gottlieb quotes are sourced to a specific broadcast appearance (CNBC's Squawk Box, Monday). Trump's Friday comments are attributed to a reporter exchange.

One flag: the article states Makary "was pressured by Trump earlier this month to authorize flavored vapes" without citation, date, or named source — this is a significant factual claim presented in authorial voice that a reader cannot independently verify from the text. Similarly, "The Trump administration has been consulting former HHS officials on potential acting leadership" rests on no named source, only unattributed reporting.

Framing — Mixed

1. "stumbles" and "weak leadership" — these pointed evaluative terms appear in a Gottlieb quote, which is appropriate attribution; however, the article does not offer Makary or FDA a response to these characterizations, giving them more weight than a single-source quote would warrant.
2. "mounting frustration" — authorial-voice framing with no sourcing. The piece states this as established fact rather than as reporting from named or even anonymous sources.
3. The White House quote — "Fake News media distractions" — is included without any framing beyond attribution, leaving an asymmetry: Gottlieb's criticism of Makary is contextualized with detail (specific failures cited), while the White House's dismissal is quoted and dropped.
4. The sequencing places Makary's continuing work first, then Gottlieb's criticism last, giving criticism the final word — a structural framing choice that tips the piece's overall impression.

Source balance

Ratio: One substantive critical voice (Gottlieb) vs. one official deflection (White House) vs. one neutral scheduler. No defender of Makary's record is quoted. The piece is notably better than a pure 1-sided story because the White House quote and Makary's own press-release statement appear, but no congressional ally, FDA career official, or policy expert endorsing Makary's approach is included.

Omissions

1. Nature of the underlying policy disputes. The article mentions "multiple policy fights" driving frustration but names only mifepristone telehealth prescribing and flavored vapes in passing. A reader has no basis to assess whether the frustration is substantive or political without knowing what Makary actually did or refused to do.
2. Gottlieb's conflict of interest is disclosed but not contextualized. The piece correctly notes Gottlieb sits on Pfizer and UnitedHealth boards, but does not note that Pfizer is an FDA-regulated company with active interests in FDA leadership — a relevant consideration when evaluating his criticism.
3. Historical precedent for removal of sitting FDA commissioners. It is rare for an FDA commissioner to be ousted mid-term; that context would help readers gauge the significance of the reported plans.
4. Staff attrition figures. The article mentions "substantial employee attrition following Department of Government Efficiency cuts" without numbers, leaving the claim unanchored.
5. Cassidy primary details. The article notes Trump endorsed a challenger to Cassidy but gives no indication of when the primary is or how competitive it is — context relevant to assessing how much political friction a Senate confirmation battle would actually entail.

What it does well

• Gottlieb's board affiliations are disclosed inline: "who serves on the boards of several companies including Pfizer and UnitedHealth Group" — a transparency practice many brief wire stories skip.
• The piece captures the institutional contradiction clearly: Makary is simultaneously "still being quoted in FDA press releases" and reportedly on the verge of removal, which is the core news tension.
• Named, on-record sourcing for the scheduling confirmation ("Yes, it's still on as scheduled") grounds the lead concretely rather than relying on anonymous tips.
• The Cassidy-confirmation obstacle is a genuinely useful piece of structural context — "a nominee would need to pass muster with the Senate Committee on Health, Education, Labor and Pensions" — that most readers would not know.

Rating

Overall: 6/10 — A competent breaking brief with on-record sourcing at its core, undercut by unattributed factual assertions, a single critical voice left unchallenged, and thin context on the policy disputes driving the story.